12:00 AM
 | 
Jul 01, 2013
 |  BC Week In Review  |  Company News  |  Deals

InSite, Merck deal

InSite regained North American development rights to AzaSite Xtra 2% azithromycin ophthalmic solution from Inspire Pharmaceuticals Inc., which Merck acquired in 2011. A joint development committee between InSite and Merck will oversee development and...

Read the full 166 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >